GenMark Diagnostics (GNMK) Earns News Impact Rating of 0.06
News coverage about GenMark Diagnostics (NASDAQ:GNMK) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GenMark Diagnostics earned a news impact score of 0.06 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 45.0213615057755 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s analysis:
- GenMark Diagnostics, Inc. (GNMK) SVP Sells $12,888.06 in Stock (americanbankingnews.com)
- Hany Massarany Sells 8,252 Shares of GenMark Diagnostics, Inc. (GNMK) Stock (americanbankingnews.com)
- Scott Mendel Sells 2,879 Shares of GenMark Diagnostics, Inc. (GNMK) Stock (americanbankingnews.com)
- GenMark Diagnostics, Inc. (GNMK) Given a $11.00 Price Target by BTIG Research Analysts (americanbankingnews.com)
- ETFs with exposure to GenMark Diagnostics, Inc. : November 21, 2017 (finance.yahoo.com)
A number of brokerages have recently issued reports on GNMK. Canaccord Genuity restated a “buy” rating on shares of GenMark Diagnostics in a research report on Wednesday, September 27th. Cowen Inc reiterated an “outperform” rating and issued a $17.00 price objective on shares of GenMark Diagnostics in a research note on Wednesday, August 2nd. BidaskClub lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. BTIG Research set a $11.00 price target on shares of GenMark Diagnostics and gave the stock a “buy” rating in a report on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of GenMark Diagnostics in a report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $11.80.
GenMark Diagnostics (NASDAQ:GNMK) opened at $4.64 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.77. GenMark Diagnostics has a 52-week low of $3.63 and a 52-week high of $13.67.
GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 100.33%. The company had revenue of $11.60 million for the quarter, compared to the consensus estimate of $14.56 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. GenMark Diagnostics’s revenue was up 7.4% compared to the same quarter last year. sell-side analysts anticipate that GenMark Diagnostics will post -1.17 earnings per share for the current fiscal year.
In related news, Director Michael Kagnoff bought 20,000 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were purchased at an average price of $4.13 per share, with a total value of $82,600.00. Following the transaction, the director now owns 64,413 shares in the company, valued at approximately $266,025.69. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jennifer Anne Williams sold 38,681 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $9.08, for a total value of $351,223.48. Following the completion of the transaction, the senior vice president now directly owns 155,889 shares in the company, valued at approximately $1,415,472.12. The disclosure for this sale can be found here. Insiders sold a total of 59,650 shares of company stock valued at $471,189 over the last quarter. 7.50% of the stock is owned by corporate insiders.
WARNING: “GenMark Diagnostics (GNMK) Earns News Impact Rating of 0.06” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/genmark-diagnostics-gnmk-earns-news-impact-rating-of-0-06/1723707.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.